Acquisitions - Schedule of Consideration Paid for IPR&D (Detail) - QrumPharma $ in Thousands |
1 Months Ended |
|---|---|
|
Dec. 31, 2020
USD ($)
| |
| Business Acquisition [Line Items] | |
| Cash consideration | $ 3,574 |
| Stock consideration (3,067,179 shares at $3.01 per share) | 9,250 |
| Transaction costs | 531 |
| Repayment of debt | 11 |
| Liabilities assumed | 22 |
| Cash acquired | (155) |
| Total consideration paid for IPR&D | $ 13,233 |
| X | ||||||||||
- Definition Business acquisition, repayment of debt. No definition available.
|
| X | ||||||||||
- Definition Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. No definition available.
|
| X | ||||||||||
- Definition Amount of consideration transferred, consisting of acquisition-date fair value of assets transferred by the acquirer, liabilities incurred by the acquirer, and equity interest issued by the acquirer. Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
|
| X | ||||||||||
- Definition Amount of equity interests of the acquirer, including instruments or interests issued or issuable in consideration for the business combination. Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
|
| X | ||||||||||
- Definition Amount of liabilities incurred by the acquirer as part of consideration transferred in a business combination. Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
|
| X | ||||||||||
- Definition The cash inflow associated with the acquisition of business during the period (for example, cash that was held by the acquired business). Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
|
| X | ||||||||||
- Definition The amount of cash paid during the reporting period for charges associated with the mergers. Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
|
| X | ||||||||||
- Definition The cash outflow associated with the acquisition of business during the period. The cash portion only of the acquisition price. Reference 1: http://www.xbrl.org/2003/role/disclosureRef
|
| X | ||||||||||
- Details
|